HISUN(SH:600267) Mei Ri Jing Ji Xin Wen·2025-10-27 12:06Group 1 - The core viewpoint of the article highlights the financial performance of Haizheng Pharmaceutical for the third quarter of 2025, indicating a slight increase in revenue but a decline in net profit and earnings per share [1] Group 2 - Haizheng Pharmaceutical reported revenue of approximately 7.923 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 0.61% [1] - The net profit attributable to shareholders of the listed company was approximately 461 million yuan, showing a year-on-year decrease of 10.55% [1] - The basic earnings per share were 0.4 yuan, reflecting a year-on-year decrease of 9.09% [1] - As of the report date, Haizheng Pharmaceutical's market capitalization stood at 12.6 billion yuan [2]